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Objective: Telavancin is approved to treat complicated skin and skin structure
infections, hospital-acquired, and ventilator-associated bacterial pneumonia caused
by Staphylococcus aureus. A previous meta-analysis of randomized controlled trials
suggested that it might be an alternative to vancomycin in cases of difficult-to-treat
meticillin-resistant S. aureus infections. We did a meta-analysis including one new trial to
access the efficacy and safety of telavancin.
Methods: We searched PubMed, Cochrane Central Register of Controlled Trials,
EMBASE and ClinicalTrials.gov up to December 30, 2015 to identify randomized
controlled trials that assessed the clinical efficacy, eradication efficiency, adverse events
and laboratory abnormalities of telavancin vs. other antibiotic agents for bacterial
infection. Meta-analysis was performed using Review Manager 5.3.0.
Results: Five studies (3790 participants) were included in the meta-analysis. There was
no significant difference in treatment success with telavancin than with control antibiotic
agents. The pooled pathogen eradication for the telavancin group was numerically higher
than that for the control groups, but there was no significant difference. While all-cause
mortalities and serious adverse events were comparable between telavancin and control
antibiotic agents, adverse event-related withdrawals (OR 1.47, 95% CI 1.13–1.91) were
higher in telavancin group. The total number adverse events were more in the telavancin
group than in the control groups, especially in the digestive system (OR 1.57, 95% CI
1.37–1.79), nervous system (OR 2.14, 95% CI 1.86–2.47) and urogenital system (OR
2.54, 95% CI 1.99–3.25). Serum creatinine increase (OR 2.25, 95% Cl 1.78–2.85) and
hypokalemia (OR 1.74, 95% CI 1.19–2.53) occurred more frequently in telavancin group
compared to control groups.
Conclusion: Telavancin may be as effective as but no better than the comparison
therapy for S. aureus infection. However, because of the high risk of adverse
event-related withdrawals and potential nephrotoxicity, prudence with the clinical use
of telavancin in infections is required.
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INTRODUCTION
Staphylococcus aureus is one of the most common and virulent
clinically encountered Gram-positive bacteria (Spink and Ferris,
1945). This pathogen causes serious invasive infections, such as
community acquired and nosocomial pneumonia, endocarditis,
soft tissue infections, and bacteremia (Drew, 2007). In 2006,
results of the Surveillance Network USA showed that nearly
60% of hospital-derived S. aureus isolates were meticillin-
resistant S. aureus (Styers et al., 2006). Staphylococcus aureus
has become a major cause of hospital-acquired pneumonia
(HAP) with meticillin-resistant S. aureus (MRSA) as the
predominant pathogen. Currently, glycopeptide antibiotics such
as vancomycin and teicoplanin are the gold standard for the
treatment of serious infections caused by Gram-positive bacteria,
especially MRSA. The emergence and prevalence of multidrug-
resistant Gram-positive pathogens underscores the urgent need
for development of new antimicrobials.
Telavancin is a novel lipoglycopeptide antibiotic derived from
vancomycin. Telavancin exhibited concentration-dependent
bactericidal effects by at least two mechanisms. It not only
inhibited late-stage peptidoglycan biosynthesis in a substrate-
dependent fashion, but also perturbed bacterial cell membrane
potential and permeability (Higgins et al., 2005). It is intended
for use to combat infections caused by S. aureus and other
Gram-positive bacteria, including methicillin resistant and
vancomycin-intermediate strains of S. aureus (MRSA and VISA,
respectively). In the US, telavancin was approved for complicated
skin and skin structure infections (cSSSI) in September 2009
and for hospital-acquired and ventilator-associated bacterial
pneumonia caused by S. aureus in June 2013. In Europe,
telavancin had been approved as second-line treatment for
hospital-acquired pneumonia, including ventilator-associated
pneumonia (VAP), known or suspected to be caused by MRSA
when other alternatives are not suitable (Rubinstein et al.,
2011a).
So far, several studies have suggested that telavancin
had comparable efficacy and higher MRSA eradication
rate comparing with other antibiotics for the treatment of
gram-positive bacteria (Stryjewski et al., 2005, 2006, 2008,
2014; Rubinstein et al., 2011b). However, Theravance Inc., a
pharmaceutical company producing telavancin (brand name as
VIBATIV), was one of the affiliations of all aforementioned
studies, thus creating a potential factor of biase. Some
retrospective reviews and traditional reviews also studied
the efficacy and safety of telavancin. However, without quality
evaluation of including articles and statistical calculation of
the data, the results were often influenced by subjective factors
and biases (Dunbar et al., 2008; Chang et al., 2010; Hooper and
Smith, 2012; Rubinstein et al., 2014; Nnedu and Pankey, 2015).
Konstantinos A. Polyzos and colleagues did a meta-analysis to
synthetically assess the efficacy and safety of telavancin, but it
was limited to six published randomized controlled trials up
to March 2012 (Polyzos et al., 2012). In addition, they only
focused on the eradication of MRSA for cSSSI, but did not report
the eradication of total S. aureus and methicillin-susceptible
S. aureus (MSSA).
Therefore, we aimed to update Konstantinos A. Polyzos
and colleagues’ meta-analysis involving efficacy and safety of
telavancin comparing with other antibiotics, and to give a clear
insight of its clinical efficacy, adverse events and laboratory
abnormalities by synthesis of the results of existing trials.
MATERIALS AND METHODS
This meta-analysis was reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) checklist.
Data Sources
A computerized search in PubMed, Cochrane Central Register
of Controlled Trials and EMBASE up to December 30, 2015 was
conducted independently by two individuals (Zhu and Zhong)
with the search terms “telavancin” or “TD-6424.” We also did
a search in ClinicalTrials.gov up to December 30, 2015 to
screen completed trials about telavancin but with no published
results. Furthermore, the references of retrieved literatures were
manually screened for more eligible studies.
Selection of Studies
Studies that met the following criteria were considered as eligible
for this meta-analysis (1) they were randomized controlled trials
(RCTs); (2) studies compared the outcomes of telavancin and
other antibiotic agents in infection treatment; (3) studies assessed
the clinical efficacy, efficiency for eradication of pathogens,
adverse events and laboratory abnormalities of both therapeutic
regimens. Two independent reviewers searched the databases
and screened all retrieved articles according to the inclusion
criteria. Studies were excluded if they were animal studies,
retrospective studies, post-hoc analyses, bactericidal activity
studies, pharmacokinetic, or pharmacodynamic studies.
Data Extraction
Two of our authors (Zhang andHe) independently extracted data
for each eligible study. In cases of discrepancy, a third author
(Chuan) was consulted. The following information was recorded
for the included trials: study title, name of first author, year
of publication, study design, type of infection, drug regimens,
treatment duration, time to test of cure (TOC), number of
patients, clinical and microbiological outcomes, and data on
safety.
The Intention-to-Treat (ITT) population included all
randomized patients in the group to which they were randomly
assigned, regardless of the treatment they actually received,
and regardless of subsequent withdrawl from treatment or
deviation from the protocol (Fisher et al., 1989). The modified
Intention-to-Treat (mITT) population referred to all patients
that received at least one dose of study drug. The clinically
evaluable (CE) population was patients in the mITT population
who complied with all exclusion and inclusion criteria and had
a clinical response of either cure or failure as assessed at the
TOC visit. The microbiologically evaluable (ME) population
consisted of CE patients who had a gram-positive pathogen
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FIGURE 1 | PRISMA Flow Diagram of the Meta-analysis.
recovered from baseline respiratory specimens or blood cultures
(Stryjewski et al., 2006).
Assessment of Risk of Bias
The quality of included studies was evaluated according to
The Cochrane Collaboration’s tool for assessing risk of bias:
random sequence generation; allocation concealment; blinding
of participants, personnel and outcome assessment; incomplete
outcome data or selective reporting; and other sources of bias
(Higgins and Green, 2011). One point was awarded for each
criterion, with a maximum score of 5. Studies scored 3 or more
were considered as high quality studies, whereas studies scored
2 or fewer points were classified into low-quality studies (Tasina
et al., 2011).
Outcomes
The primary outcome examined in the meta-analysis was
treatment success in the mITT, CE, and ME populations, which
was defined as resolution of clinically significant signs and
symptoms associated with cSSSI, HAP or other infection diseases,
or was defined as improvement to the extent that the infectious
process had been controlled and no further antimicrobial therapy
was necessary. Secondary outcomes included the pathogen
eradication, adverse effects (AEs) and laboratory abnormalities.
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Eradication of pathogens was based on ME populations. Adverse
effects and laboratory abnormalities were assessed in mITT
populations.
Statistical Analysis
The statistical analyses were carried out in Review Manager
(version 5.3.0) (Cochrane Collaboration, Oxford, United
Kingdom). Random effects model (REM) was chosen since the
included studies involving different infections, different control
regimens, different sample size, which introduced obvious
heterogeneity across the trials. Odds ratio (OR), with 95%
confidence interval (CI), was used for all primary and secondary
outcomes by Mantel-Haenszel method. The publication bias was
not assessed due to the small number of the included studies.
Sensitivity analysis was performed to investigate the influence on
the overall results by omitting a single trial at a time.
RESULTS
Selected Studies and Their Characteristics
The outcome of the search was shown in Figure 1. Four hundred
and ninety seven papers were identified after initial searching.
Fifty three articles were excluded because of repeated reports.
Among the remaining studies, 421 studies were excluded after
reading titles, abstracts or texts. Only 23 were retrieved full text
for eligibility, of which 18 studies were excluded (Corey et al.,
2007b,a, 2014; Stryjewski et al., 2008, 2012, 2013; Wilson et al.,
2009; Barriere, 2010, 2014; Rubinstein et al., 2011a, 2014; Hooper
and Smith, 2012; Nannini et al., 2012; Barriere et al., 2014a,b;
Torres et al., 2014; Lacy et al., 2015). Thus, five studies comparing
telavancin with control regimens were included in the meta-
analysis (Stryjewski et al., 2005, 2006, 2008, 2014; Rubinstein
et al., 2011b; Figure 1).
Baseline characteristics of the studies included in this analysis
were presented in Table 1. All 5 studies were multicentre double-
blind trials and privately funded by the pharmaceutical industry.
The average age of participants was 42.3–60 years. Three studies
received quality scores of 3 and the other two received 2
(Table 1). Three studies involved patients with complicated
skin and skin structure infections (cSSSI) and compared
telavancin intravenous (IV) at 10mg/kg/24 h or 7.5mg/kg/24 h
with standard therapy (1 g of vancomycin every 12 h, 2 g of
nafcillin or oxacillin every 6 h, or 0.5–1 g of cloxacillin every 6 h;
Stryjewski et al., 2005, 2006, 2008). One study involved patients
with hospital-acquired pneumonia and compared telavancin at
10mg/kg/24 h with vancomycin at a dosage of 1 g IV every 12 h
(Rubinstein et al., 2011b). One study involved patients with
uncomplicated S. aureus bacteremia and compared telavancin IV
at 10mg/kg/24 h with standard therapy (vancomycin 1 g IV q
12 h, or nafcillin 2 g IV q 6 h, oxacillin 2 g IV q 6 h, or cloxacillin
2 g IV q 6 h; Stryjewski et al., 2014).
Treatment Success in mITT, CE, and ME
Populations
Assessment of treatment success was based on mITT, CE, and
ME population. There was no significant difference in treatment
success in the mITT population between patients treated with
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FIGURE 2 | Treatment success based on mITT, CE, and ME populations. Df, degrees of freedom; M-H, Mantel-Haenszel method.
telavancin and those treated with comparators (5 studies, 3790
participants, OR = 1.02, 95% CI = 0.89–1.18, P = 0.74;
Figure 2). The same was true for ME population (5 studies, 2650
participants, OR= 1.46, 95% CI= 0.64–3.34, P= 0.37, Figure 2)
and CE patients (5 studies, 1832 participants, OR = 1.23, 95%
CI = 0.94–1.62, P = 0.36; Figure 2). The results of two largest
study groups (Stryjewski et al., 2008; Rubinstein et al., 2011b) had
no effect on the overall results when they were removed one by
one or both.
Pathogen Eradication in ME Population
The total pathogen eradication for the telavancin group was
numerically higher than that for the comparator group in the
ME population at the TOC visit, but there was no significant
difference (4 studies, 1313 participants, OR = 1.30, 95% CI =
0.88–1.94, P = 0.19, Figure 3). More specifically, treatment with
telavancin was associated with numerically higher eradication
rate for total S. aureus, MSSA (for S. aureus, 1477 strains,
OR= 1.31, 95% CI = 0.99–1.75, P = 0.06; for MSSA, 459
strains, OR = 1.25, 95% CI = 0.66–2.38, P = 0.50, Figure 3).
Treatment with telavancin was associated with almost the same
eradication rate for MRSA and Streptococcus pneumoniae (for
MRSA, 964 strains, OR = 1.42, 95% CI = 0.94–2.14, P = 0.10;
for Streptococcus pneumoniae, 146 strains, OR = 0.99, 95% CI =
0.30–3.29, P= 0.98, Figure 3). However, there were no significant
differences in eradication for all these species.
Adverse Effects
The total number of adverse events in the telavancin groups
was higher than the number in the comparators in the
mITT population, but there was no significant difference
(5 studies, 3790 participants, OR = 1.17, 95% CI =
0.89–1.54, P = 0.26; Figure 4). Overall, mortality rate (3
studies; 3428 participants, OR = 1.10, 95% CI = 0.86–
1.41, P = 0.45; Figure 4) and serious adverse events (5
studies, 3790 participants, OR = 1.41, 95% CI = 0.99–1.99,
P = 0.06; Figure 4) were comparable between telavancin
and comparators. Discontinuance due to adverse events (5
studies, 3790 participants, OR = 1.47, 95% CI = 1.13–1.91,
P = 0.004; Figure 4) was more common in the telavancin
group based on the mITT population. Assessment of detailed
adverse events showed a higher incidence in digestive system,
nervous system and urogenital system in participants receiving
telavancin than in control groups (Figure 5). There was no
significant difference in the proportions of patients who
developed adverse events in the metabolic and nutritional
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FIGURE 3 | Pathogen eradication in total and for total Staphylococcus aureus, MSSA, MRSA, and Streptococcus pneumonia. Df, degrees of freedom;
M-H, Mantel-Haenszel method.
system, hemic and lymphatic system, cardiovascular system,
respiratory system and body as a whole between the compared
regimens. Significantly fewer episodes of adverse events in
the skin/appendages were reported in the telavancin groups
(Figure 5).
Laboratory Abnormalities
Significant increase in serum creatinine was more frequently
observed in telavancin group compared to control group
(OR= 2.25, 95% CI = 1.78–2.85; Figure 6). Moreover,
hypokalemia also occurred more frequently in telavancin
group than in control group (OR= 1.74, 95% CI = 1.19–2.53;
Figure 6). There was no difference in alkaline phosphatase
(AKP) increase, aspartate transaminase (AST) and/or alanine
transaminase (ALT) increase, anemia, leukopenia, platelet
decrease, eosinophilia, hyperkalemia and microalbuminuria
between telavancin group and control group (Figure 6).
Pooled odds ratios were calculated from random-effects
models with the Mantel-Haenszel method.
DISCUSSION
The present meta-analysis demonstrated the noninferiority of
telavancin comparing with comparator antibiotics for cSSSI,
HAP and uncomplicated S. aureus bacteremia. Telavancin
exhibited no significant difference in eradication rate for
total S. aureus and MRSA comparing with control group.
One issue that need to be addressed was that the American
Thoracic Society and Infectious Diseases Society of America
(IDSA) guidelines recommended 15–20µg/mL of vancomycin
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FIGURE 4 | Total adverse events, mortality, serious adverse events and withdrawal related to studied medications. Df, degrees of freedom; M-H,
Mantel-Haenszel method.
FIGURE 5 | Detailed adverse events of telavancin vs. comparator antibiotics. Pooled odds ratios were calculated from random-effects models with the
Mantel-Haenszel method.
for serious infections, such as pneumonia and severe skin and
soft tissue infections (Liu et al., 2011). In fact, 34% participants
had a trough vancomycin level ≤ 10µg/mL in the trials for
HAP and 14% participants had a trough vancomycin level ≤
5µg/mL in the trials for cSSSI. The number of patients with a
level ≤ 15µg/mL was conceivably much higher. A considerable
proportion of participants from vancomycin group did not
receive a reasonable trough level according to the IDSA
guidelines. Thus, one can only state that telavancin was not
inferior to underdosed vancomycin. But it was not sufficient to
claim that telavancin and vancomycin have comparable efficacy
since vancomycin was underdosed (Tarchini, 2011). Therefore,
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FIGURE 6 | Laboratory abnormalities of telavancin vs. comparator antibiotics.
telavancin is no better than standard antimicrobial regimens,
for the treatment of cSSSI, HAP and uncomplicated S. aureus
bacteremia, since it is associated with a higher frequency of
withdrawl due to adverse effects, especially in the urogenital
system. Among HAP patients with kidney dysfunction and pre-
existing moderate-to-severe renal impairment, 28-day survival
rates for telavancin were lower than vancomycin (Corey et al.,
2014; Nnedu and Pankey, 2015).
In Polyzos and colleagues’ meta-analysis of telavancin
(Polyzos et al., 2012), results were similar to those results in our
analysis for all outcomes except for eradication of MRSA. Of all
5 studies including in our mete- analysis, three studies involved
patients with cSSSI, one study involving patients with HAP
and one study involving patients with uncomplicated S. aureus
bacteremia. We analyzed the synthesis eradication of MRSA for
all the trials while Polyzos and colleagues only focused on that for
cSSSI. In Polyzos and colleagues’ meta-analysis, eradication rate
of MRSA was significantly higher with telavancin than that with
comparator regimens (OR = 1.71, 95% CI 1.08–2.70), whereas
the difference was not significant in our study (OR = 1.42, 95%
CI 0.94–2.14). The results were the same between Polyzos’s meta-
analysis and our study when the data from trials involving HAP
and uncomplicated S. aureus bacteremia were removed. Thus,
these results suggested that telavancin showed higher eradication
rate of MRSA for cSSSI but not for HAP and uncomplicated
S. aureus bacteremia.
There were several limitations in our study. Only one new
study assessing the treatment of telavancin for uncomplicated
S. aureus bacteremia was added in this meta-analysis. It was a
multinational, double-blind phase II randomized clinical trial
with 58 participants. Its sample size was too small to affect the
overall synthetic outcomes. We searched the ClinicalTrials.gov
for completed trials with no published data. There was only one
open-label, non-randomized phase I tiral and we failed to obtain
the unpublished data. Finally, all of the five included studies
(7 trials) were sponsored by Theravance Inc., a pharmaceutical
company producing telavancin (brand name as VIBATIV). This
could be considered a factor that might introduce bias in the
assessment of outcomes.
CONCLUSIONS
In conclusion, telavancin has clinical efficacy andmicrobiological
eradication rate similar to control antimicrobial regimens
in S. aureus infection, including MRSA infection. However,
telavancin is associated with a higher frequency of adverse events
than the comparators, especially in the digestive system, nervous
system and urogenital system. Because of significant serum
creatinine increase and consequent potential nephrotoxicity,
prudence with the clinical use of telavancin in infections is
required.
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